Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

Bristol Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube Mar 9, 2026
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube Mar 9, 2026
Policy / Regulatory

China Announces New Hospital Inspection Measures to Standardize Healthcare System

Fineline Cube Dec 20, 2023

The National Health Commission (NHC), in collaboration with the National Administration of Traditional Chinese Medicine...

Company Deals

MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers

Fineline Cube Dec 20, 2023

US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership...

Company Deals

Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma

Fineline Cube Dec 20, 2023

Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...

Company Deals

Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China

Fineline Cube Dec 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...

Company Drug

Konruns Pharmaceutical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma

Fineline Cube Dec 20, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Drug

Staidson Pharmaceutical’s BDB-001 Earns Breakthrough Therapy Designation in China for AAV Treatment

Fineline Cube Dec 20, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that its...

Company Drug

3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study

Fineline Cube Dec 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...

Company Drug

Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China

Fineline Cube Dec 20, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...

Company Deals

Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions

Fineline Cube Dec 20, 2023

Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences

Fineline Cube Dec 20, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...

Company Deals

China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer

Fineline Cube Dec 19, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...

Company Deals

Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market

Fineline Cube Dec 19, 2023

Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...

Company Drug

European Commission Expands Keytruda Indications for Advanced Cancer Treatments

Fineline Cube Dec 19, 2023

The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...

Company Drug

HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD

Fineline Cube Dec 19, 2023

HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...

Company Deals

Blue Sail Medical Partners with Weifang Government on Healthcare Initiative

Fineline Cube Dec 19, 2023

China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...

Company Drug

HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors

Fineline Cube Dec 19, 2023

Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...

Company Deals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Fineline Cube Dec 19, 2023

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...

Company Drug

EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment

Fineline Cube Dec 19, 2023

Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Company Medical Device

BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit

Fineline Cube Dec 19, 2023

BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China

Fineline Cube Dec 19, 2023

According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...

Posts pagination

1 … 393 394 395 … 632

Recent updates

  • Bristol Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis
  • Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets
  • Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers
  • Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations
  • CSPC’s SYH2059 Inhalation Powder Wins FDA IND Approval – PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bristol Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.